MedPage Today8h
Clozapine's REMS Program on the Chopping Block at Upcoming FDA Meeting
"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
Opinion - Is the FDA contributing to the homelessness crisis?
The FDA's REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
FDA grants orphan drug designation to potential treatment of STXBP1 developmental and epileptic encephalopathy
Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
STAT21h
FDA commissioner: We need action and higher-quality research on ultra-processed foods
Researchers, public health and health care groups, advocates, industry, and the public must put tackling diet-related disease ...
New FDA rules for TV drug ads: Simpler language and no distractions
The new rules, which cover both TV and radio, instruct drugmakers to use simple, consumer-friendly language when describing ...
TMCnet1d
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI™ (dexmedetomidine ... treatment of agitation associated with bipolar I or II disorder or schizophrenia in the ...
verywellhealth3d
The Surprising Role of Ketamine in Combatting Depression: A Pharmacist's Insight
Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...
Reviva Announces Enrollment Update For Open Label Extension Study Evaluating Brilaroxazine In Schizophrenia
Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Morningstar4d
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
"These results have clear positive read-through to Bristol Myers," wrote William Blair analysts Matt Phipps and Myles Minter in a note released Monday, pointing to the recent Food and Drug ...